A significant milestone achieved, Actinogen has enrolled final patient into XanADu. A total of 186 patients have been enrolled into XanADu, surpassing initial target of 174.
Find out more on XanADu, Xanamem and cortisol in Alzheimer’s and other neurological diseases. View video with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board
First participant dosed in XanaHES, a Ph 1 dose escalation safety study of Xanamem in healthy elderly volunteers. “We are very excited to have reached yet another important milestone in the development of Xanamem …” said Dr Bill Ketelbey
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.
Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.
"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."
|11.02.2019||First participant dosed in important new Xanamem study: XanaHES|
|29.01.2019||December 2018 Quarterly Update|
|07.01.2019||ACW Presents at SACHS Neuroscience Forum during JPM Week|